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Under obese conditions, adipose tissue can become oxygen-deficient or hypoxic. Exten-
sive work has been done using various diet-induced obesity models to demonstrate an
important role of hypoxia-induced signaling in adipose tissue and its impact on adipose
functions related to adipogenesis, insulin sensitivity, and inflammation. We have recently
identified a new mechanism connecting activation of the hypoxia-sensing pathway mani-
fested by hypoxia-inducible factor (HIF) 2α to adipose tissue inflammation and hypertrophic
cardiomyopathy. Interestingly, this observation is consistent with the clinical evidence
showing that obesity is often associated with ventricular hypertrophy and dysfunction as
well as congestive heart failure independent of other well-established risk factors includ-
ing diabetes, hypertension, and coronary artery disease. This brief review will discuss the
currently published genetic mouse models to determine the role of the HIF pathway in
adipose tissue-associated diseases with a focus on the newly identified role of adipocyte
HIF-2 in the development of hypertrophic cardiomyopathy.
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INTRODUCTION
Molecular oxygen (O2) is essential for maintaining normal tissue
functions from cellular energy production to regulation of a mul-
titude of intracellular signal transduction pathways. Under obese
conditions, O2 concentrations in adipose tissue can be negatively
affected by a number of factors. Pathological obesity is often asso-
ciated with adipocyte hypertrophy (1–3). Enlarged adipocytes can
reduce the effective range of O2 diffusion in adipose tissue. On
the other hand, O2 supply to adipose tissue is reduced because of
decreased capillary density as well as subdued blood flow in obese
subjects compared to lean subjects [see reviews by Ye (4) and Tray-
hurn (5)]. As shown by a recent study, obesity and high fat diet
(HFD) can also increase O2 consumption in adipocytes likely due
to uncoupled respiration induced by free fatty acids (6). As a result
of these and other changes, insufficient oxygenation, i.e., hypoxia
occurs in adipose tissue under pathologically obese conditions.
Using a needle-type pO2 microelectrode to directly measured
tissue pO2 concentrations, Ye et al. have found that the average
pO2 is low at 15.2 mmHg in adipose tissue of the genetically obese
ob/ob mice compared to the average of 47.9 mmHg in that of lean
mice (7). Decreased adipose pO2 has further been independently
confirmed in HFD-induced obese mice and ob/ob mice (8, 9). Adi-
pose tissue hypoxia is also found in humans. The mean adipose
pO2 in overweight or obese patients is approximately 15% lower
than that of lean subjects; adipose pO2 decreases even further with
increasing body fat percentage (10). Such direct evidence indicates
that adipose tissue hypoxia is a common pathological feature of
obese subjects. In contrast, other studies have found no evidence
of obesity-associated hypoxia in human abdominal subcutaneous
fat (11, 12). These discrepancies in adipose tissue oxygenation are
likely due to the use of different pO2 measurement techniques [see
review by Hodson (13)] as well as fat depot-dependent differences
in O2 supply and consumption.
Increasing amounts of evidence nonetheless suggest that
hypoxia can exert profound impact on adipose tissue function.
It has been shown that hypoxia inhibits adipogenic differentiation
(14, 15), which may further enhance adipocyte hypertrophy due
to inadequate de novo adipogenesis (16). Hypoxia affects glucose
homeostasis, lipid metabolism, and production of adipokines and
pro-inflammatory cytokines in adipose tissue (7, 10, 17). It has
also been shown that macrophages are preferentially localized in
hypoxic regions of adipose tissue with obesity (8). These obser-
vations strongly suggest adipose tissue hypoxia is an important
etiological entity closely involved in onset and/or progression of
obesity-associated diseases.
THE HYPOXIA-INDUCIBLE FACTOR PATHWAY
Mammalian cells respond to pO2 variations via the canonical
multi-step O2-sensing pathway leading to the eventual activation
of the hypoxia-inducible factors (HIF), a class of heterodimeric
transcription factors containing the basic helix-loop-helix and
PER/SIM/aryl hydrocarbon receptor nuclear translocator (ARNT)
(bHLH-PAS) domains (Figure 1). Each heterodimer consists of
an O2-sensitive HIF-α (HIF-1α or HIF-2α) and the O2-insensitive
HIF-1β subunit (18). The quintessential aspect of this pathway is
the O2-dependent regulation of HIF-α protein stability. Changes
in pO2 are first“sensed”by HIF prolyl hydroxylases (PHDs), a fam-
ily of O2-binding dioxygenases (19–22). In mammals, HIF-α pro-
teins are regulated primarily by three PHD isoforms (PHD1, 2, and
3) among which PHD2 is the most abundant and widely expressed
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FIGURE 1 |The hypoxia-inducible factor (HIF) pathway (see text for
details).
hydroxylase (23, 24). Under normoxic conditions, PHDs catalyze
hydroxylation of the two conserved proline residues within the
O2-dependent degradation domain (ODD) of HIF-1α or HIF-2α
subunit. The hydroxylated HIF-α proteins interact with the von
Hippel–Lindau tumor suppressor protein pVHL, undergo polyu-
biquitination, and are finally degraded by proteasomes (25). Under
hypoxic conditions (e.g., <2% O2), PHDs are rendered inactive
and HIF-α is no longer hydroxylated. The stabilized HIF-α forms
a dimer with the constitutively expressed HIF-1β to activate tran-
scription of a wide range of genes including those involved in
the regulation of angiogenesis, metabolism, and inflammation
(18, 26).
Murine Hif1a mRNA is expressed in both mature adipocytes
and progenitor cells (14, 15), whereas both Hif2a mRNA and
HIF-2α protein are found in differentiated adipocytes even under
normoxic conditions (14), suggesting that HIF-2α might have a
unique role in mature adipocytes. Animal model studies have
shown that HIF-1α protein levels (7), as well as HIF DNA-binding
activities (27), are elevated in adipose tissue of obese mice. In addi-
tion, HIF-2α protein levels are also increased in adipose tissue of
mice fed with HFD for 4 weeks (28). However, activation of HIF-1
leads to suppression of adipogenesis (14, 15). Collectively, these
observations suggest that the HIF pathway can play a potentially
significant role in obesity, diabetes, and metabolic syndrome (29).
The efforts to study the whole-body effects of the HIF-
dependent O2-sensing pathway have been hampered by the
embryonic lethality of homozygous deletion of the key genes of
this pathway including Hif1a, Hif2a, Hif1b, Phd2, and Vhl. Several
genetic mouse models have nonetheless demonstrated a global
impact of the HIF pathway on body weight and metabolism.
Hif1a+/− mice are viable but gain slightly less weight under nor-
moxia but lost significantly more weight when maintained at 10%
ambient O2 compared to wild-type littermates (30). Zhang et al.
(31) have found that glucose increases HIF-2α protein synthesis
and stability in proopiomelanocortin (POMC) neurons. Genetic
deletion of Hif1b in POMC neurons facilitates obesity develop-
ment via impaired hypothalamic glucose sensing (31). On the
other hand, the PHD2 hypomorphic (Hif-p4h-2gt/gt) mice have less
adipose tissue, smaller adipocytes, but improved glucose tolerance
and insulin sensitivity, as well as less adipose tissue inflammation
compared to their wild-type littermates (32). In this review, we
will focus on the adipocyte-specific knockout mouse models.
GENETIC MOUSE MODELS TO INVESTIGATE THE ROLE OF
THE HIF PATHWAY IN ADIPOCYTES
A number of genetic approaches have been used to either inactivate
or activate the HIF pathway in adipocytes. The tissue-specific gene
deletion or knockout is achieved by adipocyte-targeted expression
of the cre recombinase under the transcriptional control by the
gene promoter of fatty acid binding protein 4 (Fabp4) or aP2.
The majority of currently published work uses either of the two
aP2-cre mouse strains: one is developed by Dr. Ronald M. Evans’
group of the Salk Institute (33) and commercially available from
the Jackson Laboratory (#005069), and the other is created by Dr.
Barbara B. Kahn’s group of the Beth Israel Deaconess Medical Cen-
ter and Harvard Medical School (34). Although the same 5.4-kbp
aP2 gene promoter/enhancer region was used to generate the aP2-
cre construct, the two strains of aP2-cre transgenic mice appear to
show differences in tissue-specific expression of cre, which is likely
due to different sites of integration of the aP2-cre transgene in the
moue genome. Two reports have shown that the Evans/aP2-cre
strain has leaky expression in brain and liver during embryonic
development (35, 36). As an alternative to the aP2 promoter, the
promoter of adiponectin (Apn), another adipocyte-specific gene,
has been used to generate transgenic mice with adipocyte-targeted
gene expression (9). Although Apn expression appears to be more
restricted to adipocytes than aP2, both genes can be expressed
albeit at lower levels in other tissues. Transcription of Apn and
aP2 also appears to be differentially regulated in adipocytes (37–
39). Therefore, it is highly possible that the phenotypes of mice
derived from the Apn-transgenic mice would not be identical to
those derived from the aP2-transgenic mice. It is also worth noting
that the promoter/enhancer fragment used for controlling trans-
gene expression contains limited numbers of enhancer elements
only and thus is not likely to fully recapitulate the expression profile
of the corresponding endogenous gene.
HIF INACTIVATION IN ADIPOCYTES
The direct role of the HIF pathway in adipocytes in live ani-
mals has been examined using two transgenic mouse approaches:
adipocyte-targeted expression of a dominant-negative HIF
(dnHIF) and cre-mediated deletion of individual HIF genes in
adipocytes. Two groups generated mouse models with targeted
deletion of HIF-1β, a common binding partner for both HIF-
1α and HIF-2α, in adipocytes by crossing mice carrying floxed
Hif1b alleles (Hif1bf/f) with the Kahn/aP2-cre mice (40, 41). Both
groups found that mice with adipocyte-targeted Hif1b deletion
were lean with reduced fat formation and were protected from
HFD-induced glucose intolerance compared to wild-type litter-
mates under the same conditions (40, 41). Adipose expression of
glucose transporter 1 (Glut1) was decreased (40, 41) and glucose
uptake by adipocytes was also reduced (41) in the adipocyte-
targeted Hif1b knockout mice. Furthermore, both expression of
vascular endothelial growth factor (Vegf) and vascular permeabil-
ity were decreased in fat tissues of the adipocyte-targeted Hif1b
knockout mice although vascular density was unchanged in fat
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(41). These independent results demonstrate an important role of
HIF-1β in the regulation of formation, development, and function
of adipocytes. However, it should bear in mind that HIF-1β, also
known as ARNT, can also interact with a number of other proteins
(42, 43) and therefore, some of the HIF-1β-associated phenotypes
may be unrelated to the HIF pathway.
As discussed above, functions of the HIF pathway are mani-
fested primarily by HIF-1 and/or HIF-2. A recently published work
(6) examined the respective and collective roles of HIF-1α and
HIF-2α in adipocytes using mouse models with adipocyte-targeted
deletion of either Hif1a (HAKO) or Hif2a (H2AKO) as well as
double knockout of both Hif1a and Hif2a (DHKO) that were gen-
erated by crossing with the Evans/aP2-cre transgenic mice. The
main phenotypes of HAKO mice are in good agreement with an
independent study using a similar HIF-1α knockout mouse model
generated from the Evans/aP2-cre transgenic mice (44). The body
weights of HAKO and H2AKO mice were, by and large, compara-
ble to that of wild-type littermates fed with regular chow or HFD,
which was somewhat inconsistent with the lean phenotype of the
adipocyte-targeted Hif1b knockout mice (40, 41). Nonetheless, the
vascular density in adipose tissue was little changed in HAKO mice,
just like that of the Hif1b knockout mice (41). Interestingly, HAKO
mice were refractory to HFD-induced insulin resistance, which
was also found in mice with adipocyte-targeted deletion of HIF-
1α generated by cross-breeding with the Kahn/aP2-cre mice (40).
Furthermore, HAKO mice resisted the development of adipose
inflammation induced by HFD as compared to their wild-type lit-
termates (6). In contrast to adipocyte-targeted deletion of HIF-1α,
loss of HIF-2α in adipocytes resulted in more pronounced HFD-
induced inflammation, glucose intolerance, and insulin resistance
compared to wild-type littermates (6). On the other hand, DHKO
mice with adipocyte-targeted deletion of both Hif1a and Hif2a
exhibited the same phenotype as that of the HAKO mice. These
results suggest that HIF-1α and HIF-2αhave opposing functions in
adipocytes with HIF-2α playing a protective role whereas HIF-1α
facilitating adipose tissue pathology under HFD conditions.
Alternatively, Zhang et al. (45) created a transgenic C57Bl/
6xCBA mouse model in which a dominant-negative HIF-1α
(dnHIF-1α) protein lacking amino acids 30–389 was selectively
expressed in adipocytes under the transcriptional control by the
5.4-kpb aP2 promoter/enhancer region. The dnHIF-1α trans-
genic mice gained weight more quickly and had more body fat
mass than the wild-type littermates did on either regular chow
or HFD (45). These mice also developed glucose intolerance and
insulin resistance especially when fed with HFD. Furthermore,
the dnHIF-1α transgenic mice exhibited increased sizes of lipid
droplets but decreased mitochondrial biogenesis and angiogenesis
in interscapular brown adipose tissue (BAT) (45). These findings
are somewhat opposite to those from the Hif1a knockout models
(6, 40, 41). It is possible that dnHIF-1α retains some of the HIF-
1α functions and thus cannot fully recapitulate the genetic loss of
Hif1a.
Sun et al. generated a double transgenic mouse (C57BL/6)
model with doxycycline (DOX)-inducible overexpression of the
dnHIF-1α protein lacking amino acids 30–389 (TRE-dnHIF-1α)
under the control by the adiponectin promoter-driven-rtTA trans-
gene (Apn-rtTA) (9). In contrast to the aP2 promoter-driven
dnHIF-1α (45), Apn promoter-driven overexpression of dnHIF-
1α in adipose tissue results in decreased body weight gain and
adipocyte size but increased energy expenditure and improved
insulin sensitivity in the transgenic mice on HFD (9). These incon-
sistencies between these two transgenic studies are likely due to
differences in promoters driving the same dnHIF-1α and modes of
gene regulation, i.e., constitutive versus DOX-induced expression.
Nonetheless, the observations made by Sun et al. are consistent
with those found in mice with adipocyte-targeted Hif1b deletion
(40, 41). Also in agreement with the Hif1a knockout study (6),
DOX-induced overexpression of dn-HIF-1α reduced local adipose
tissue inflammation in HFD-fed transgenic mice (9).
HIF ACTIVATION IN ADIPOCYTES
Halberg et al. generated a transgenic FVB mouse model with
adipocyte-targeted expression of a constitutively active HIF-1α
mutant lacking amino acids 401–603 (ODD) under the control
of the 5.4-kbp aP2 promoter/enhancer (27). Expression of the
HIF-1α-∆ODD mutant varied significantly in a depot-dependent
manner with, relatively speaking, the highest level of expression
in subcutaneous fat and the lowest in epididymal fat (27). Con-
sistent with high transgene expression, there was a significant
increase in the sizes of subcutaneous adipocytes. The hemizy-
gous transgenic mice gained more weight than their wild-type
littermates did on either regular chow diet or HFD. Plasma glu-
cose concentrations of the HIF-1α-∆ODD transgenic mice were
moderately higher than those of their wild-type littermates dur-
ing the oral glucose tolerance test. Furthermore, overexpression
of HIF-1α-∆ODD in adipocytes resulted in local inflammation
and fibrosis in adipose tissue (27). It is quite surprising that
some of the phenotypes exhibited by transgenic mice express-
ing the constitutively active HIF-1α lacking amino acids 401–603
are rather similar to those displayed by transgenic mice express-
ing the dnHIF-1α without amino acids 30–389 (9, 45). It remains
to be seen whether the unexpectedly similar results from these
two opposite approaches could be due to the shared C-terminal
domain of HIF-1α in addition to other genetic differences in these
two transgenic strains.
In contrast to the transgenic approach, the endogenous HIF
pathway can be activated as a result of genetic deletion of a
HIF prolyl 4-hydroxylase or the VHL gene, which leads to sta-
bilization of both HIF-1α and HIF-2α proteins. Being the most
commonly expressed member of the PHD family, Phd2 has been
targeted for genetic deletion. Matsuura et al. generated a mouse
model (Phd2f/f/ap2-Cre) with adipocyte-targeted deletion of Phd2
using the Evans/aP2-cre transgenic mice (46). The epididymal
white fat pads of the Phd2f/f/ap2-Cre mice weighed less and the
adipocytes were smaller in size compared to wild-type littermates.
The Phd2f/f/ap2-Cre mice were resistant to HFD-induced obe-
sity and exhibited improved glucose homeostasis. Expression of
pro-inflammatory cytokines in epididymal white fat was compa-
rable between Phd2f/f/ap2-Cre mice and their wild-type littermates
under the same HFD conditions,although macrophage infiltration
appeared to be reduced in epididymal white fat Phd2f/f/ap2-Cre
mice (46).
Using the same genetic approach, Michailidou et al. have
made quite different observations (47). Mice with deletion of
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Phd2 in adipocytes (aP2-Phd2KO) gained more weight mainly
with larger white adipose tissue mass and bigger adipocytes than
their wild-type littermates fed with the same chow diet. The
increased adiposity correlated with enhanced angiogenesis in the
aP2-Phd2KO adipose tissue. Nonetheless, the aP2-Phd2KO mice
showed no significant differences in glucose homeostasis but basal
lipolysis was significantly lower compared to that of wild-type
controls (47).
In addition to PHD2, PHD1 and PHD3 can also catalyze pro-
line hydroxylation of HIF-1α and HIF-2α proteins. Therefore,
possibilities exist that loss of PHD2 might, at least, be partially
compensated by PHD1 and/or PHD3 in adipocytes. As reported
by Matsuura et al., Phd3 mRNA levels increased by several fold
whereas the increase of Phd1 mRNA levels was not significant
in white fat of Phd2f/f/aP2-Cre mice (46). Furthermore, expres-
sion of Hif1a and Hif2a mRNA was increased more than twofold
in adipose tissue of the Phd2f/f/aP2-Cre mice (46). In contrast,
Michailidou et al. found that expression of Phd1 and Phd3 mRNA
in adipose tissue was not affected in their aP2-Phd2KO mice
(47). Using the murine 3T3-L1-derived adipocytes, Floyd et al.
found that pharmacological inhibition of PHD activity did not
consistently affect HIF-1α protein levels, suggesting that other
pathways might also be involved in HIF activation (48). These
differences, among others, may partially explain why there are so
many discrepancies between these two studies despite their nearly
identical genetic approach using the same Evans/aP2-cre trans-
genic mice from the Jackson Laboratory and the same congenic
C57Bl6 genetic background.
In contrast to the multiple isoforms of PHDs, there is only one
VHL gene in mammals. Therefore, genetic deletion of the VHL
gene would be a more efficient approach to activate the entire
HIF pathway without compensation by other isoforms. We cre-
ated a genetic mouse model (fatVHLko) with adipocyte-targeted
deletion of Vhl by crossing the Vhlf/f mice with the Kahn/aP2-
cre transgenic mice (17). Consistent with reports from other
groups who used the Kahn/aP2-cre transgenic mice (34, 36, 49,
50), genetic deletion of Vhl was highly restricted to adipocytes.
Both brown and white adipocytes of the homozygous fatVH-
Lko mice were enlarged in size, consistent with the findings from
the aP2-Phd2KO mice (47). The fatVHLko mice showed normal
fetal development and no apparent defects at birth. Interscapular
brown fat developed normally although intracellular fat contents
were significantly increased. In contrast, visceral white fat was
generally reduced, suggesting a depot-dependent effect of HIF
activation or Vhl deletion on adipose development. It is worth
noting that reduced white fat development of fatVHLko mice (17)
is similar to that found in Phd2f/f/ap2-Cre mice (46). Because
hypoxia or HIF activation can suppress adipogenic differentia-
tion of preadipocytes (14, 15), it is possible that white fat tissue
development may be more sensitive than brown fat tissue to HIF-
dependent inhibition of adipogenesis. This concept is further
supported by the finding that levels of Hif1a and Hif2a mRNA were
significantly increased in white fat tissue of Phd2f/f/aP2-Cre mice
(46), suggesting that further elevated HIF activation in adipocytes
of Phd2f/f/ap2-Cre mice potentially contributes to reduction of
white adipose tissue.
HIF-2, ADIPOSE INFLAMMATION, AND HYPERTROPHIC
CARDIOMYOPATHY
Some 50 years ago, it was reported (51) that increase in heart
weight above the predicted normal value was proportional to the
increase of body weight over the normal range and grossly obese
patients presented with ventricular hypertrophy as the predom-
inant and most specific alteration in the heart. Ensuing studies
further found that obese patients often developed cardiomyopathy
with increased wall thickness and cavity volume of the left ventri-
cle (52). As discussed below, activation of the hypoxia-sensing
pathway in adipocytes could potentially be a leading cause of
obesity-associated cardiomyopathy.
As our study has shown, all fatVHLko mice developed car-
diomegaly within 7 days after birth, while all other major organs
appeared to develop normally (17). Incidentally, this is also the
time frame when rapid adipose tissue development occurs post-
natally (53). The heart of fatVHLko mice showed enlarged atria,
ventricles, and wall thicknesses. Cardiomyocyte hypertrophy and
increased numbers of Ki67+ cells, along with increased cardiac
angiogenesis, were apparent in the heart. There was also fibrosis
in the heart of fatVHLko mice. Functions of the fatVHLko heart
were also compromised with reduced ejection fraction, increased
end diastolic pressure, and decreased dynamic regulation of blood
pressure, especially −dP/dt. The fatVHLko mice died in early
adulthood with a median survival time of 10 weeks, likely due
to sudden heart failure (17). This phenotype occurred in the
homozygous fatVHLko mice only as Vhl heterozygous mice were
developmentally indistinguishable from wild-type littermates. In
contrast to this study, the Phd2f/f/aP2-Cre mice appeared to
have normal cardiac development (46), whereas the heart phe-
notype was not examined in the aP2-Phd2KO mice (47). The
differences between Vhl knockout and Phd2 knockout could be
attributed, in part, to the potential compensation by other PHD
isoforms and the different strains of the aP2-cre mice, as discussed
above.
As primary effectors of the hypoxia-signaling pathway, both
HIF-1α and HIF-2α proteins are stabilized with Vhl deletion,
but they have non-overlapping functions (54). We further created
mouse models with different combinations of adipocyte-specific
double or triple knockout to determine the differential roles of
HIF-1α and HIF-2α in the pathological progression of fatVHLko
mice (17). Genetic deletion of both Vhl and Hif2a completely nor-
malized the development of the fatVHLko mice with no apparent
signs of any developmental or behavioral defects. In stark contrast,
deletion of Hif1a together with Vhl (fatVHL1Ako) significantly
exacerbated hypertrophic cardiomyopathy and resulted in much
earlier onset of death with a median survival time of only 4 weeks
for fatVHL1Ako mice (17). These results suggest that chronic acti-
vation of HIF-2α, but not HIF-1α, in adipocytes is the main cause
of adipose tissue pathology and hypertrophic cardiomyopathy.
Consistent with these findings, cardiac abnormalities were not
found in transgenic mice with adipocyte-targeted expression of
the constitutively active HIF-1α-∆ODD (27) although the study
by Lee et al. suggested otherwise (6).
The basal plasma glucose levels of fatVHLko mice were lower
than those of their wild-type littermates. The fatVHLko mice
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showed by and large normal responses to intraperitoneal injec-
tion of glucose or insulin and showed moderate abnormalities in
lipid metabolism. These findings suggest that the development
of hypertrophic heart disease in pathologically obese subjects is
likely independent of insulin resistance and/or hyperlipidemia,
two commonly regarded key risk factors for cardiovascular dis-
eases. Nevertheless, adipocyte-targeted deletion of Vhl led to
both systemic and local adipose tissue inflammation. Expres-
sion of immunoglobulin genes, chemokines (Ccl2, Ccl3, Ccl7, and
Ccl8), and cytokines (Il1b, Il6, and Tnf) was robustly increased
in Vhl-deleted adipose tissue. Serum levels of IL-1β, IL-6, MCP-
1/CCL2, and TNFα among others were also significantly increased
in fatVHLko mice. Consistent with the systemic inflammatory
phenotype, the NFκB pathway is strongly activated in the heart
of fatVHLko mice (17). Furthermore, the NFAT pathway, a key
player in development of cardiac hypertrophy (55), was also acti-
vated in the heart of fatVHLko mice (17). Consistent with these
observations, it has been shown that NFκB can activate NFAT
via protein–protein interaction to induce cardiac hypertrophy
(56). Collectively, these findings strongly support the emerging
concept that chronic inflammation is a leading cause of heart
diseases (57–61).
Mechanistically, the inflammation phenotype was mainly
dependent on activation of HIF-2α because double knockout
of Vhl with Hif2a, but not with Hif1a, normalized expression
of pro-inflammatory genes in adipose tissue and reduced acti-
vation of NFκB and the NFAT pathways (17). These results
clearly demonstrate that HIF-1α and HIF-2α play fundamen-
tally different roles in adipocytes. Importantly, chronic acti-
vation of HIF-2α in adipocytes elicits local inflammation in
adipose tissue and increases production of circulating pro-
inflammatory cytokines and chemokines, which then induces
hypertrophic cardiomyopathy by activating NFκB and NFAT
pathways.
Several similarities can be drawn between the fatVHLko mod-
els and clinical obesity with regard to the heart phenotype.
Both clinical and epidemiological studies have shown that obe-
sity is associated with left ventricle dysfunction and heart fail-
ure independent of diabetes, hypertension, and coronary artery
disease (52). Some obese patients develop ventricular hypertro-
phy and congestive heart failure without other comorbidities in
the heart (51, 62) while others present with diastolic dysfunc-
tions but without hypertension (63). Similarly, the fatVHLko and
fatVHL1Ako mice develop lethal cardiomegaly without present-
ing with severely compromised heart functions except reduced
diastolic −dP/dt or significant metabolic abnormalities includ-
ing insulin resistance and hyperlipidemia (17). In light of adi-
pose tissue hypoxia associated with severe obesity (7, 10, 27),
our study has led to a new disease mechanism underlying the
etiology of obesity-associated cardiomyopathy. As this model sug-
gests, obesity-induced pathological changes adipose tissue, such
as adipocyte hypertrophy, decreased O2 supply, and increased
O2 consumption, lead to the development of adipose tissue
hypoxia that, in turn, induces sustained activation of HIF-2α in
adipocytes, which then results in both local and systemic inflam-
mation, and contributes to the development of hypertrophic
cardiomyopathy.
SUMMARY
The various genetic mouse model studies discussed above have
illustrated an important role of the HIF pathway in adipose tis-
sue under both physiological and pathological conditions, despite
a lack of consistent observations in some of the studies. New
genetic approaches would be required to further clarify these
inconsistent results. Nonetheless, the current studies have pre-
sented strong evidence showing that HIF pathway can play a
critical role in the development of adipose tissue inflammation and
other pathological abnormalities reminiscent of obesity-induced
diseases including obesity-associated hypertrophic cardiomyopa-
thy. Pharmacological intervention of the HIF pathway will likely
have the potential to control the progression of obesity and
obesity-related symptoms.
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